{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-016660","form_type":"8-K","ticker":null,"cik":"0001840904","company_name":"ATAI Life Sciences N.V.","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.074580+00:00","generated_at":"2026-05-23T02:40:06.159441+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ATAI Life Sciences CBO Sahil Kirpekar departs; separation and consulting agreements finalized","bullets":["Sahil Kirpekar terminated as Chief Business Officer effective April 2, 2025; separation agreement signed April 24.","Separation provides up to $5,000 legal fee reimbursement, extended option exercise to Aug 14, 2025, $3,400 learning costs, $12,000 relocation, company computer retention.","Consulting agreement effective April 3 for transitional BD support through Dec 31, 2025; allows vesting of 50% of unvested options from Mar 2023 and Mar 2024 grants.","No replacement named; Kirpekar continues as consultant for business development transition."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-016660","json":"https://secwatch.observer/filing/0001140361-25-016660.json","markdown":"https://secwatch.observer/filing/0001140361-25-016660.md","text":"https://secwatch.observer/filing/0001140361-25-016660.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125016660/0001140361-25-016660-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125016660/ef20048125_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T02:40:06.159441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a8ae886cee","claim":"Sahil Kirpekar was terminated as Chief Business Officer at ATAI Life Sciences N.V..","evidence_excerpt":"Sahil Kirpekar’s employment as Chief Business Officer of atai Life Sciences US, Inc. (“atai US”) and its affiliates, including atai Life Sciences N.V. (the “Company”), terminated effective April 2, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125016660/0001140361-25-016660-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Business Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}